Scinopharm Taiwan (TPE:1789) Total Equity: NT$10,525 Mil (As of Dec. 2025)


TPE:1789 Scinopharm Taiwan Ltd TPE:1789
75 GF Score
Price NT$20.85
GF Value NT$27.15
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Scinopharm Taiwan Total Equity?

Scinopharm Taiwan TPE:1789 +2.71% 75 Total Equity is NT$10,525 Mil as of Dec. 2025. GuruFocus rates TPE:1789 with a GF Score™ of 75/100 and a GF Value™ of NT$27.15 (Modestly Undervalued). The stock has 8 warning signs investors should review.

Scinopharm Taiwan's total equity for the quarter that ended in Dec. 2025 was NT$10,525 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Scinopharm Taiwan Total Equity Historical Data

* Premium members only.

The historical data trend for Scinopharm Taiwan's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scinopharm Taiwan Total Equity Chart

Scinopharm Taiwan Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10,511.05 10,450.05 10,364.43 10,525.80 10,524.74

Scinopharm Taiwan Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10,525.80 10,685.06 10,268.46 10,992.95 10,524.74
TPE:1789
75GF Score
Scinopharm Taiwan Ltd TPE:1789
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scinopharm Taiwan Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Scinopharm Taiwan's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=11857.725-1332.988
=10,525

Scinopharm Taiwan's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=11857.725-1332.988
=10,525

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of NT$10,525 Mil mean?
Scinopharm Taiwan (TPE:1789) has a Total Equity of NT$10,525 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Scinopharm Taiwan and its competitors.
Is Scinopharm Taiwan's Total Equity too high?
Scinopharm Taiwan's current Total Equity is NT$10,525 Mil. Overall, Scinopharm Taiwan has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scinopharm Taiwan's Total Equity compare to ZTS and UTHR?
Scinopharm Taiwan's Total Equity of NT$10,525 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Scinopharm Taiwan and its competitors. Scinopharm Taiwan's current Total Equity is NT$10,525 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinopharm Taiwan stock overvalued right now?
Based on GuruFocus' analysis, Scinopharm Taiwan (TPE:1789) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$27.15, compared to a current price of NT$20.85 — trading 23.2% below its estimated fair value. The current Total Equity is NT$10,525 Mil. Scinopharm Taiwan's overall GF Score™ is 75/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Scinopharm Taiwan (TPE:1789), the current Total Equity is NT$10,525 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Scinopharm Taiwan (TPE:1789) Overvalued in 2026?

Based on GuruFocus' analysis, Scinopharm Taiwan stock appears to be undervalued. The current stock price of NT$20.85 is trading 23.2% below its estimated GF Value™ of NT$27.15. GuruFocus considers Scinopharm Taiwan to be Modestly Undervalued.

Key valuation signals for TPE:1789:

  • Total Equity: NT$10,525 Mil
  • GF Value™: NT$27.15 vs. price of NT$20.85 (23.2% below fair value)
  • GF Score™: 75/100 with 8 warning signs

No single metric tells the full story. See the TPE:1789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Scinopharm Taiwan Business Description

Address Nan-Ke 8th Road, No. 1, Southern Taiwan Science Park, Shan-Hua, Tainan, TWN, 74144
Scinopharm Taiwan Ltd is mainly engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade, and the research, development, production, manufacture, and sales of Active Pharmaceutical Ingredients (API), albumin medicines, oligonucleotide medicines, peptide medicines, injections, and new small molecule drugs. The Company also provides related consulting and technical services and international trade for the above products. In addition, the Company sells chemical material reprocessed from material recycled from the Company's manufacturing process.
75GF Score

Get the complete analysis for TPE:1789

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$20.85
Price
NT$27.15
GF Value